Intentar ORO - Gratis
REGULATE MEDICAL AESTHETICS
Bio Spectrum
|November 2020
The market that is worth billions of dollars in India has witnessed significant growth in the demand for aesthetic procedures owing to the rise in the number of doctors and surgeons providing effective medical aesthetic treatments and the launch of technologically advanced products for the same. However, India lacks proper guidelines to regulate the use of specific products and procedures for aesthetic treatment.

Over the years, the robust digital footprint of India has played an instrumental role in driving the growth of technology in the healthcare market. Going by the figures, as per Invest India, the Indian healthcare industry is projected to be an approximately $372 billion industry by 2022. This growth can also be credited to significant diversification of healthcare services and easy accessibility for a large part of the society. As a result, healthcare is not only a need now but also a lifestyle requirement.
One such lifestyle element in the healthcare market is the medical aesthetics industry. The desire among the Indian population to look young, fit, presentable and contemporary has led to the demand of several medical aesthetics procedures such as skin tightening, cosmetic implants, hair removal, hair restoration, body contouring to name a few.
In the past two decades, medical aesthetic procedures have become increasingly popular. The market that is worth billions of dollars in India has witnessed significant growth in the demand for aesthetic procedures owing to the rise in the number of doctors and surgeons providing effective medical aesthetic treatments and the launch of technologically advanced products for the same.
“Reports about the growth of the medical aesthetics market in India say that at the moment it is ballooning at 10 per cent CAGR annually with a steady or increasing growth rate expected with time. Back in 2018, a growth of 5.5 per cent CAGR per annum and a target of $73.6 billion mark were expected by 2022. The market has grown more than anticipated and is growing faster than expected”, says Dr Debraj Shome, Director, The Esthetic Clinics, Mumbai.
Esta historia es de la edición November 2020 de Bio Spectrum.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Translate
Change font size